Using JAK inhibitors to improve health in individuals with Down syndrome
JAK Inhibition in Down Syndrome
This study is looking at how a type of medicine called JAK inhibitors can help adults with Down syndrome who have autoimmune issues, by seeing if it can reduce inflammation and improve their overall health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10903970 on NIH RePORTER |
What this research studies
This research investigates how JAK inhibitors can help manage autoimmune conditions in adults with Down syndrome, who often experience a unique disease spectrum due to Trisomy 21. The study aims to understand the safety and effectiveness of these medications by examining their impact on immune dysregulation and related health issues. Participants will be monitored for their response to treatment, focusing on the potential benefits of reducing inflammation and improving overall health outcomes. This clinical trial represents a novel approach to addressing the specific health challenges faced by this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with Down syndrome who are experiencing autoimmune conditions or related health issues.
Not a fit: Patients without Down syndrome or those not affected by autoimmune conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of autoimmune conditions and better overall health for individuals with Down syndrome.
How similar studies have performed: While the specific application of JAK inhibitors in Down syndrome is novel, similar approaches have shown promise in managing autoimmune diseases in other populations.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Espinosa, Joaquin M. — University of Colorado Denver
- Study coordinator: Espinosa, Joaquin M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.